{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:08:09Z","timestamp":1794690489144,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":128,"publisher":"Springer US","isbn-type":[{"value":"9781071617519","type":"print"},{"value":"9781071617526","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1752-6_21","type":"book-chapter","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T16:02:28Z","timestamp":1636646548000},"page":"307-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lipopeptide Pepducins as Therapeutic Agents"],"prefix":"10.1007","author":[{"given":"Emily","family":"Michael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Kuliopulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"issue":"5480","key":"21_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.289.5480.739","volume":"289","author":"K Palczewski","year":"2000","unstructured":"Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (New York, NY) 289(5480):739\u2013745","journal-title":"Science (New York, NY)"},{"issue":"1","key":"21_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cell.2012.09.003","volume":"151","author":"M Audet","year":"2012","unstructured":"Audet M, Bouvier M (2012) Restructuring G-protein-coupled receptor activation. Cell 151(1):14\u201323. https:\/\/doi.org\/10.1016\/j.cell.2012.09.003","journal-title":"Cell"},{"issue":"2","key":"21_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1073\/pnas.022460899","volume":"99","author":"L Covic","year":"2002","unstructured":"Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A 99(2):643\u2013648. https:\/\/doi.org\/10.1073\/pnas.022460899","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"21_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2009.12.1520","volume":"98","author":"KB Fontanini","year":"2010","unstructured":"Fontanini KB, Janz J, Looby R, Hamilton JA (2010) Rapid binding and transmembrane diffusion of pepducins in phospholipid bilayers. Biophys J 98(3):278a. https:\/\/doi.org\/10.1016\/j.bpj.2009.12.1520","journal-title":"Biophys J"},{"issue":"16","key":"21_CR5","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1074\/jbc.R112.355461","volume":"287","author":"K O\u2019Callaghan","year":"2012","unstructured":"O\u2019Callaghan K, Kuliopulos A, Covic L (2012) Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 287(16):12787\u201312796. https:\/\/doi.org\/10.1074\/jbc.R112.355461","journal-title":"J Biol Chem"},{"key":"21_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellsig.2017.09.005","volume":"41","author":"A Nieto Gutierrez","year":"2018","unstructured":"Nieto Gutierrez A, McDonald PH (2018) GPCRs: emerging anti-cancer drug targets. Cell Signal 41:65\u201374","journal-title":"Cell Signal"},{"issue":"12","key":"21_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser AS, Attwood MM, Rask-Andersen M, Schi\u00f6th HB, Gloriam DE (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16(12):829\u2013842. https:\/\/doi.org\/10.1038\/nrd.2017.178","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"21_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/1389450120666181105152439","volume":"20","author":"S Saikia","year":"2019","unstructured":"Saikia S, Bordoloi M, Sarmah R (2019) Established and in-trial GPCR families in clinical trials: a review for target selection. Curr Drug Targets 20(5):522\u2013539. https:\/\/doi.org\/10.2174\/1389450120666181105152439","journal-title":"Curr Drug Targets"},{"issue":"1","key":"21_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/atvbaha.115.306777","volume":"36","author":"PA Gurbel","year":"2016","unstructured":"Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A (2016) Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol 36(1):189\u2013197. https:\/\/doi.org\/10.1161\/atvbaha.115.306777","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"21_CR10","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.7150\/thno.26619","volume":"8","author":"LA Grisanti","year":"2018","unstructured":"Grisanti LA, Thomas TP, Carter RL, de Lucia C, Gao E, Koch WJ, Benovic JL, Tilley DG (2018) Pepducin-mediated cardioprotection via \u03b2-arrestin-biased \u03b22-adrenergic receptor-specific signaling. Theranostics 8(17):4664\u20134678. https:\/\/doi.org\/10.7150\/thno.26619","journal-title":"Theranostics"},{"issue":"28","key":"21_CR11","doi-asserted-by":"publisher","first-page":"E4107","DOI":"10.1073\/pnas.1606267113","volume":"113","author":"R Carr 3rd","year":"2016","unstructured":"Carr R 3rd, Schilling J, Song J, Carter RL, Du Y, Yoo SM, Traynham CJ, Koch WJ, Cheung JY, Tilley DG, Benovic JL (2016) \u03b2-Arrestin-biased signaling through the \u03b22-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A 113(28):E4107\u2013E4116. https:\/\/doi.org\/10.1073\/pnas.1606267113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"21_CR12","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1161\/ATVBAHA.120.315168","volume":"40","author":"A Kuliopulos","year":"2020","unstructured":"Kuliopulos A, Gurbel Paul A, Rade Jeffrey J, Kimmelstiel Carey D, Turner Susan E, Bliden Kevin P, Fletcher Elizabeth K, Cox Daniel H, Covic L (2020) PAR1 (protease-activated receptor 1) pepducin therapy targeting myocardial necrosis in coronary artery disease and acute coronary syndrome patients undergoing cardiac catheterization. Arterioscler Thromb Vasc Biol 40(12):2990\u20133003. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315168","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"21_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jid.2018.08.019","volume":"139","author":"TP Barr","year":"2019","unstructured":"Barr TP, Garzia C, Guha S, Fletcher EK, Nguyen N, Wieschhaus AJ, Ferrer L, Covic L, Kuliopulos A (2019) PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol 139(2):412\u2013421. https:\/\/doi.org\/10.1016\/j.jid.2018.08.019","journal-title":"J Invest Dermatol"},{"issue":"44","key":"21_CR14","doi-asserted-by":"publisher","first-page":"23188","DOI":"10.1074\/jbc.M116.732743","volume":"291","author":"AM Shearer","year":"2016","unstructured":"Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kuliopulos A (2016) Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) pepducin. J Biol Chem 291(44):23188\u201323198. https:\/\/doi.org\/10.1074\/jbc.M116.732743","journal-title":"J Biol Chem"},{"issue":"5","key":"21_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/gutjnl-2015-310344","volume":"66","author":"V Wieser","year":"2017","unstructured":"Wieser V, Adolph TE, Enrich B, Kuliopulos A, Kaser A, Tilg H, Kaneider NC (2017) Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors. Gut 66(5):930\u2013938. https:\/\/doi.org\/10.1136\/gutjnl-2015-310344","journal-title":"Gut"},{"issue":"1","key":"21_CR16","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/atvbaha.120.315154","volume":"41","author":"L Van Doren","year":"2021","unstructured":"Van Doren L, Nguyen N, Garzia C, Fletcher E, Stevenson R, Jaramillo D, Kuliopulos A, Covic L (2021) Lipid receptor GPR31 (G-protein-coupled receptor 31) regulates platelet reactivity and thrombosis without affecting hemostasis. Arterioscler Thromb Vasc Biol 41(1):e33\u2013e45. https:\/\/doi.org\/10.1161\/atvbaha.120.315154","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"21_CR17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/cea.12628","volume":"45","author":"M Asaduzzaman","year":"2015","unstructured":"Asaduzzaman M, Nadeem A, Arizmendi N, Davidson C, Nichols HL, Abel M, Ionescu LI, Puttagunta L, Thebaud B, Gordon J, DeFea K, Hollenberg MD, Vliagoftis H (2015) Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. Clin Exp Allergy 45(12):1844\u20131855","journal-title":"Clin Exp Allergy"},{"key":"21_CR18","doi-asserted-by":"publisher","first-page":"104750","DOI":"10.1016\/j.phrs.2020.104750","volume":"155","author":"RL Brouillette","year":"2020","unstructured":"Brouillette RL, Besserer-Offroy \u00c9, Mona CE, Chartier M, Lavenus S, Sousbie M, Belleville K, Longpr\u00e9 JM, Marsault \u00c9, Grandbois M, Sarret P (2020) Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain. Pharmacol Res 155:104750. https:\/\/doi.org\/10.1016\/j.phrs.2020.104750","journal-title":"Pharmacol Res"},{"key":"21_CR19","doi-asserted-by":"publisher","unstructured":"Lorenzon N, Gestin M, Langel \u00dc (2020) Mimicry of dopamine 1 receptor signaling with cell-penetrating peptides. Int J Pept Res Ther. https:\/\/doi.org\/10.1007\/s10989-020-10066-y","DOI":"10.1007\/s10989-020-10066-y"},{"issue":"1","key":"21_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbrc.2020.01.058","volume":"524","author":"HY Lee","year":"2020","unstructured":"Lee HY, Kim HS, Jeong YS, Kim JC, Bae YS, Jo YH, Park JS, Bae YS (2020) A membrane-tethering pepducin derived from formyl peptide receptor 3 shows strong therapeutic effects against sepsis. Biochem Biophys Res Commun 524(1):156\u2013162. https:\/\/doi.org\/10.1016\/j.bbrc.2020.01.058","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"21_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.4555","volume":"237","author":"CW Steele","year":"2015","unstructured":"Steele CW, Karim SA, Foth M, Rishi L, Leach JD, Porter RJ, Nixon C, Jeffry Evans T, Carter CR, Nibbs RJ, Sansom OJ, Morton JP (2015) CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. J Pathol 237(1):85\u201397","journal-title":"J Pathol"},{"key":"21_CR22","doi-asserted-by":"publisher","unstructured":"Covic L, Kuliopulos A (2018) Protease-activated receptor 1 as therapeutic target in breast, lung, and ovarian cancer: pepducin approach. Int J Mol Sci 19(8). https:\/\/doi.org\/10.3390\/ijms19082237","DOI":"10.3390\/ijms19082237"},{"issue":"6","key":"21_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29(6):832\u2013845","journal-title":"Cancer Cell"},{"key":"21_CR24","doi-asserted-by":"publisher","unstructured":"Schneditz G, Elias JE, Pagano E, Zaeem Cader M, Saveljeva S, Long K, Mukhopadhyay S, Arasteh M, Lawley TD, Dougan G, Bassett A, Karlsen TH, Kaser A, Kaneider NC (2019) GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Sci Signal 12(562). https:\/\/doi.org\/10.1126\/scisignal.aau9048","DOI":"10.1126\/scisignal.aau9048"},{"issue":"11","key":"21_CR25","doi-asserted-by":"publisher","first-page":"129398","DOI":"10.1016\/j.bbagen.2019.07.007","volume":"1863","author":"M Poujol de Molliens","year":"2019","unstructured":"Poujol de Molliens M, Jamadagni P, L\u00e9tourneau M, Devost D, H\u00e9bert TE, Patten SA, Fournier A, Chatenet D (2019) Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor. Biochim Biophys Acta Gen Subj 1863(11):129398. https:\/\/doi.org\/10.1016\/j.bbagen.2019.07.007","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"7366","key":"21_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477(7366):549\u2013555. https:\/\/doi.org\/10.1038\/nature10361","journal-title":"Nature"},{"issue":"7366","key":"21_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nature10488","volume":"477","author":"KY Chung","year":"2011","unstructured":"Chung KY, Rasmussen SG, Liu T, Li S, DeVree BT, Chae PS, Calinski D, Kobilka BK, Woods VL Jr, Sunahara RK (2011) Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor. Nature 477(7366):611\u2013615. https:\/\/doi.org\/10.1038\/nature10488","journal-title":"Nature"},{"issue":"7329","key":"21_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature09648","volume":"469","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK (2011) Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469(7329):175\u2013180. https:\/\/doi.org\/10.1038\/nature09648","journal-title":"Nature"},{"issue":"7340","key":"21_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature09795","volume":"471","author":"J Standfuss","year":"2011","unstructured":"Standfuss J, Edwards PC, D\u2019Antona A, Fransen M, Xie G, Oprian DD, Schertler GF (2011) The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471(7340):656\u2013660. https:\/\/doi.org\/10.1038\/nature09795","journal-title":"Nature"},{"issue":"31","key":"21_CR30","doi-asserted-by":"publisher","first-page":"29171","DOI":"10.1074\/jbc.M103747200","volume":"276","author":"JA Ballesteros","year":"2001","unstructured":"Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA (2001) Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276(31):29171\u201329177. https:\/\/doi.org\/10.1074\/jbc.M103747200","journal-title":"J Biol Chem"},{"issue":"10","key":"21_CR31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nm760","volume":"8","author":"L Covic","year":"2002","unstructured":"Covic L, Misra M, Badar J, Singh C, Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8(10):1161\u20131165. https:\/\/doi.org\/10.1038\/nm760","journal-title":"Nat Med"},{"issue":"18","key":"21_CR32","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1039\/c3ob27445d","volume":"11","author":"M Tsuji","year":"2013","unstructured":"Tsuji M, Ueda S, Hirayama T, Okuda K, Sakaguchi Y, Isono A, Nagasawa H (2013) FRET-based imaging of transbilayer movement of pepducin in living cells by novel intracellular bioreductively activatable fluorescent probes. Org Biomol Chem 11(18):3030\u20133037. https:\/\/doi.org\/10.1039\/c3ob27445d","journal-title":"Org Biomol Chem"},{"issue":"52","key":"21_CR33","doi-asserted-by":"publisher","first-page":"35668","DOI":"10.1074\/jbc.M114.618819","volume":"289","author":"R Carr 3rd","year":"2014","unstructured":"Carr R 3rd, Du Y, Quoyer J, Panettieri RA Jr, Janz JM, Bouvier M, Kobilka BK, Benovic JL (2014) Development and characterization of pepducins as Gs-biased allosteric agonists. J Biol Chem 289(52):35668\u201335684. https:\/\/doi.org\/10.1074\/jbc.M114.618819","journal-title":"J Biol Chem"},{"issue":"1","key":"21_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/mol.115.100339","volume":"89","author":"R Carr 3rd","year":"2016","unstructured":"Carr R 3rd, Koziol-White C, Zhang J, Lam H, An SS, Tall GG, Panettieri RA Jr, Benovic JL (2016) Interdicting Gq activation in airway disease by receptor-dependent and receptor-independent mechanisms. Mol Pharmacol 89(1):94\u2013104. https:\/\/doi.org\/10.1124\/mol.115.100339","journal-title":"Mol Pharmacol"},{"issue":"6","key":"21_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nm1245","volume":"11","author":"NC Kaneider","year":"2005","unstructured":"Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 11(6):661\u2013665. https:\/\/doi.org\/10.1038\/nm1245","journal-title":"Nat Med"},{"issue":"3","key":"21_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1538-7836.2007.02364.x","volume":"5","author":"SJH Wielders","year":"2007","unstructured":"Wielders SJH, Bennaghmouch A, Reutelingsperger CPM, Bevers EM, Lindhout T (2007) Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemost 5(3):571\u2013576","journal-title":"J Thromb Haemost"},{"issue":"52","key":"21_CR37","doi-asserted-by":"publisher","first-page":"E5088","DOI":"10.1073\/pnas.1312515110","volume":"110","author":"J Quoyer","year":"2013","unstructured":"Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt SW, Bouvier M (2013) Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A 110(52):E5088\u2013E5097. https:\/\/doi.org\/10.1073\/pnas.1312515110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"21_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1196\/annals.1378.087","volume":"1091","author":"S Kubo","year":"2006","unstructured":"Kubo S, Ishiki T, Doe I, Sekiguchi F, Nishikawa H, Kawai K, Matsui H, Kawabata A (2006) Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells\/tissues. Ann N Y Acad Sci 1091:445\u2013459. https:\/\/doi.org\/10.1196\/annals.1378.087","journal-title":"Ann N Y Acad Sci"},{"key":"21_CR39","doi-asserted-by":"publisher","unstructured":"Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A (2015) Allosteric activation of a G protein coupled receptor with cell-penetrating receptor mimetics. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M115.636316","DOI":"10.1074\/jbc.M115.636316"},{"issue":"7201","key":"21_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature07063","volume":"454","author":"JH Park","year":"2008","unstructured":"Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454(7201):183\u2013187. https:\/\/doi.org\/10.1038\/nature07063","journal-title":"Nature"},{"issue":"7212","key":"21_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature07330","volume":"455","author":"P Scheerer","year":"2008","unstructured":"Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455(7212):497\u2013502. https:\/\/doi.org\/10.1038\/nature07330","journal-title":"Nature"},{"issue":"4","key":"21_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/mol.114.093328","volume":"86","author":"AJ Zweemer","year":"2014","unstructured":"Zweemer AJ, Bunnik J, Veenhuizen M, Miraglia F, Lenselink EB, Vilums M, de Vries H, Gibert A, Thiele S, Rosenkilde MM, IJzerman AP, Heitman LH (2014) Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2. Mol Pharmacol 86(4):358\u2013368. https:\/\/doi.org\/10.1124\/mol.114.093328","journal-title":"Mol Pharmacol"},{"issue":"7","key":"21_CR43","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1073\/pnas.1014863108","volume":"108","author":"L Dowal","year":"2011","unstructured":"Dowal L, Sim DS, Dilks JR, Blair P, Beaudry S, Denker BM, Koukos G, Kuliopulos A, Flaumenhaft R (2011) Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci U S A 108(7):2951\u20132956. https:\/\/doi.org\/10.1073\/pnas.1014863108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"21_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1152\/physrev.00028.2003","volume":"84","author":"VS Ossovskaya","year":"2004","unstructured":"Ossovskaya VS, Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84(2):579\u2013621. https:\/\/doi.org\/10.1152\/physrev.00028.2003","journal-title":"Physiol Rev"},{"issue":"6","key":"21_CR45","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/iub.465","volume":"63","author":"G Koukos","year":"2011","unstructured":"Koukos G, Sevigny L, Zhang P, Covic L, Kuliopulos A (2011) Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life 63(6):412\u2013418. https:\/\/doi.org\/10.1002\/iub.465","journal-title":"IUBMB Life"},{"issue":"1","key":"21_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/circulationaha.112.091918","volume":"126","author":"P Zhang","year":"2012","unstructured":"Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O\u2019Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A (2012) Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126(1):83\u201391. https:\/\/doi.org\/10.1161\/circulationaha.112.091918","journal-title":"Circulation"},{"issue":"28","key":"21_CR47","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2174\/1381612033453884","volume":"9","author":"HS Ahn","year":"2003","unstructured":"Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C (2003) Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des 9(28):2349\u20132365. https:\/\/doi.org\/10.2174\/1381612033453884","journal-title":"Curr Pharm Des"},{"issue":"6","key":"21_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/00207230500120294","volume":"16","author":"SMG Smith","year":"2005","unstructured":"Smith SMG, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, Storey RF (2005) PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 16(6):340\u2013345. https:\/\/doi.org\/10.1080\/00207230500120294","journal-title":"Platelets"},{"issue":"17","key":"21_CR49","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","volume":"123","author":"D Wiviott Stephen","year":"2011","unstructured":"Wiviott Stephen D, Flather Marcus D, O\u2019Donoghue Michelle L, Goto S, Fitzgerald Desmond J, Cura F, Aylward P, Guetta V, Dudek D, Contant Charles F, Angiolillo Dominick J, Bhatt Deepak L (2011) Randomized trial of atopaxar in the treatment of patients with coronary artery disease. Circulation 123(17):1854\u20131863. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.001404","journal-title":"Circulation"},{"issue":"2","key":"21_CR50","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cell.2009.02.018","volume":"137","author":"V Trivedi","year":"2009","unstructured":"Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O\u2019Callaghan K, Covic L, Kuliopulos A (2009) Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137(2):332\u2013343. https:\/\/doi.org\/10.1016\/j.cell.2009.02.018","journal-title":"Cell"},{"issue":"14","key":"21_CR51","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1158\/0008-5472.Can-09-4341","volume":"70","author":"A Agarwal","year":"2010","unstructured":"Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, Kuliopulos A (2010) Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 70(14):5880\u20135890. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-4341","journal-title":"Cancer Res"},{"issue":"2","key":"21_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/thoraxjnl-2013-203877","volume":"69","author":"C Lin","year":"2014","unstructured":"Lin C, Duitman J, Daalhuisen J, Ten Brink M, von der Th\u00fcsen J, van der Poll T, Borensztajn K, Spek CA (2014) Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax 69(2):152\u2013160. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-203877","journal-title":"Thorax"},{"issue":"1","key":"21_CR53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ajpath.2011.03.025","volume":"179","author":"J Cisowski","year":"2011","unstructured":"Cisowski J, O\u2019Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C, Agarwal A, Hunt SW 3rd, McMurry T, Brinckerhoff L, Covic L (2011) Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 179(1):513\u2013523. https:\/\/doi.org\/10.1016\/j.ajpath.2011.03.025","journal-title":"Am J Pathol"},{"issue":"6","key":"21_CR54","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/ATVBAHA.118.310967","volume":"38","author":"R Rana","year":"2018","unstructured":"Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A (2018) Noncanonical matrix metalloprotease 1\u2014protease-activated receptor 1 signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc Biol 38(6):1368\u20131380. https:\/\/doi.org\/10.1161\/ATVBAHA.118.310967","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"21_CR55","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","volume":"19","author":"N Mackman","year":"2020","unstructured":"Mackman N, Bergmeier W, Stouffer GA, Weitz JI (2020) Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 19(5):333\u2013352. https:\/\/doi.org\/10.1038\/s41573-020-0061-0","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"21_CR56","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00395-007-0653-4","volume":"102","author":"JL Strande","year":"2007","unstructured":"Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE (2007) SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia\/reperfusion injury in rat hearts. Basic Res Cardiol 102(4):350\u2013358. https:\/\/doi.org\/10.1007\/s00395-007-0653-4","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"21_CR57","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/1074248413485434","volume":"18","author":"DL Sonin","year":"2013","unstructured":"Sonin DL, Wakatsuki T, Routhu KV, Harmann LM, Petersen M, Meyer J, Strande JL (2013) Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J Cardiovasc Pharmacol Ther 18(5):460\u2013475. https:\/\/doi.org\/10.1177\/1074248413485434","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"20","key":"21_CR58","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/circulationaha.107.692764","volume":"116","author":"R Pawlinski","year":"2007","unstructured":"Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N (2007) Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 116(20):2298\u20132306. https:\/\/doi.org\/10.1161\/circulationaha.107.692764","journal-title":"Circulation"},{"issue":"11","key":"21_CR59","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/nm.2461","volume":"17","author":"L Badeanlou","year":"2011","unstructured":"Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F (2011) Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med 17(11):1490\u20131497. https:\/\/doi.org\/10.1038\/nm.2461","journal-title":"Nat Med"},{"issue":"6","key":"21_CR60","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.neuropharm.2005.11.024","volume":"50","author":"TJ Bushell","year":"2006","unstructured":"Bushell TJ, Plevin R, Cobb S, Irving AJ (2006) Characterization of proteinase-activated receptor 2 signalling and expression in rat hippocampal neurons and astrocytes. Neuropharmacology 50(6):714\u2013725. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.11.024","journal-title":"Neuropharmacology"},{"issue":"6","key":"21_CR61","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1681\/ASN.2015020208","volume":"27","author":"S Kumar Vr","year":"2016","unstructured":"Kumar Vr S, Darisipudi MN, Steiger S, Devarapu SK, Tato M, Kukarni OP, Mulay SR, Thomasova D, Popper B, Demleitner J, Zuchtriegel G, Reichel C, Cohen CD, Lindenmeyer MT, Liapis H, Moll S, Reid E, Stitt AW, Schott B, Gruner S, Haap W, Ebeling M, Hartmann G, Anders H-J (2016) Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications. J Am Soc Nephrol 27(6):1635. https:\/\/doi.org\/10.1681\/ASN.2015020208","journal-title":"J Am Soc Nephrol"},{"key":"21_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molmet.2019.08.019","volume":"29","author":"R Rana","year":"2019","unstructured":"Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, Abdelmalek M, Wang Y, Baleja JD, Covic L, Kuliopulos A (2019) PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab 29:99\u2013113. https:\/\/doi.org\/10.1016\/j.molmet.2019.08.019","journal-title":"Mol Metab"},{"issue":"1","key":"21_CR63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.2119\/molmed.2015.00094","volume":"21","author":"C Lin","year":"2015","unstructured":"Lin C, von der Th\u00fcsen J, Daalhuisen J, ten Brink M, Crestani B, van der Poll T, Borensztajn K, Spek CA (2015) Pharmacological targeting of protease-activated receptor 2 affords protection from bleomycin-induced pulmonary fibrosis. Mol Med 21(1):576\u2013583. https:\/\/doi.org\/10.2119\/molmed.2015.00094","journal-title":"Mol Med"},{"issue":"41","key":"21_CR64","doi-asserted-by":"publisher","first-page":"14178","DOI":"10.1523\/jneurosci.2399-12.2012","volume":"32","author":"DK Lam","year":"2012","unstructured":"Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL (2012) Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2. J Neurosci 32(41):14178\u201314183. https:\/\/doi.org\/10.1523\/jneurosci.2399-12.2012","journal-title":"J Neurosci"},{"issue":"8","key":"21_CR65","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jid.2020.01.012","volume":"140","author":"J Zhao","year":"2020","unstructured":"Zhao J, Munanairi A, Liu X-Y, Zhang J, Hu L, Hu M, Bu D, Liu L, Xie Z, Kim BS, Yang Y, Chen Z-F (2020) PAR2 mediates itch via TRPV3 signaling in keratinocytes. J Investig Dermatol 140(8):1524\u20131532","journal-title":"J Investig Dermatol"},{"issue":"20","key":"21_CR66","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.1073\/pnas.1017091108","volume":"108","author":"LM Sevigny","year":"2011","unstructured":"Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A (2011) Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A 108(20):8491\u20138496. https:\/\/doi.org\/10.1073\/pnas.1017091108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"21_CR67","doi-asserted-by":"publisher","first-page":"G516","DOI":"10.1152\/ajpgi.00296.2012","volume":"304","author":"ES Michael","year":"2013","unstructured":"Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G (2013) Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol 304(5):G516\u2013G526. https:\/\/doi.org\/10.1152\/ajpgi.00296.2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"21_CR68","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1600-0625.1999.tb00383.x","volume":"8","author":"M Steinhoff","year":"1999","unstructured":"Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH, Ansel JC, Bunnett NW (1999) Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 8(4):282\u2013294. https:\/\/doi.org\/10.1111\/j.1600-0625.1999.tb00383.x","journal-title":"Exp Dermatol"},{"issue":"13","key":"21_CR69","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1096\/fj.02-1112com","volume":"17","author":"S Seeliger","year":"2003","unstructured":"Seeliger S, Derian CK, Vergnolle N, Bunnett NW, Nawroth R, Schmelz M, Von Der Weid PY, Buddenkotte J, Sunderk\u00f6tter C, Metze D, Andrade-Gordon P, Harms E, Vestweber D, Luger TA, Steinhoff M (2003) Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J 17(13):1871\u20131885. https:\/\/doi.org\/10.1096\/fj.02-1112com","journal-title":"FASEB J"},{"key":"21_CR70","doi-asserted-by":"publisher","unstructured":"Buhl T, Ikoma A, Kempkes C, Cevikbas F, Sulk M, Buddenkotte J, Akiyama T, Crumrine D, Camerer E, Carstens E, Sch\u00f6n MP, Elias P, Coughlin SR, Steinhoff M (2020) Protease-activated receptor-2 regulates neuro-epidermal communication in atopic dermatitis. Front Immunol 11(1740). https:\/\/doi.org\/10.3389\/fimmu.2020.01740","DOI":"10.3389\/fimmu.2020.01740"},{"issue":"3","key":"21_CR71","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaci.2004.11.042","volume":"115","author":"C Ebeling","year":"2005","unstructured":"Ebeling C, Forsythe P, Ng J, Gordon JR, Hollenberg M, Vliagoftis H (2005) Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. J Allergy Clin Immunol 115(3):623\u2013630. https:\/\/doi.org\/10.1016\/j.jaci.2004.11.042","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"21_CR72","doi-asserted-by":"publisher","first-page":"560","DOI":"10.4168\/aair.2019.11.4.560","volume":"11","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Lee SH, Jeong S, Hong SJ (2019) Protease-activated receptors 2-antagonist suppresses asthma by inhibiting reactive oxygen species-thymic stromal lymphopoietin inflammation and epithelial tight junction degradation. Allergy Asthma Immunol Res 11(4):560\u2013571. https:\/\/doi.org\/10.4168\/aair.2019.11.4.560","journal-title":"Allergy Asthma Immunol Res"},{"issue":"9","key":"21_CR73","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.4049\/jimmunol.169.9.5315","volume":"169","author":"F Schmidlin","year":"2002","unstructured":"Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME (2002) Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 169(9):5315\u20135321. https:\/\/doi.org\/10.4049\/jimmunol.169.9.5315","journal-title":"J Immunol"},{"issue":"6","key":"21_CR74","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/1753425913503387","volume":"20","author":"JD de Boer","year":"2014","unstructured":"de Boer JD, Van\u2019t Veer C, Stroo I, van der Meer AJ, de Vos AF, van der Zee JS, Roelofs JJ, van der Poll T (2014) Protease-activated receptor-2 deficient mice have reduced house dust mite-evoked allergic lung inflammation. Innate Immun 20(6):618\u2013625. https:\/\/doi.org\/10.1177\/1753425913503387","journal-title":"Innate Immun"},{"issue":"5","key":"21_CR75","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1067\/mai.2001.119025","volume":"108","author":"DA Knight","year":"2001","unstructured":"Knight DA, Lim S, Scaffidi AK, Roche N, Chung KF, Stewart GA, Thompson PJ (2001) Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 108(5):797\u2013803. https:\/\/doi.org\/10.1067\/mai.2001.119025","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"21_CR76","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1164\/rccm.200808-1211OC","volume":"180","author":"S Bayat","year":"2009","unstructured":"Bayat S, Strengell S, Porra L, Janosi TZ, Petak F, Suhonen H, Suortti P, Hantos Z, Sovij\u00e4rvi AR, Habre W (2009) Methacholine and ovalbumin challenges assessed by forced oscillations and synchrotron lung imaging. Am J Respir Crit Care Med 180(4):296\u2013303. https:\/\/doi.org\/10.1164\/rccm.200808-1211OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"21_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1465-9921-5-15","volume":"5","author":"GR Zosky","year":"2004","unstructured":"Zosky GR, von Garnier C, Stumbles PA, Holt PG, Sly PD, Turner DJ (2004) The pattern of methacholine responsiveness in mice is dependent on antigen challenge dose. Respir Res 5(1):15\u201315. https:\/\/doi.org\/10.1186\/1465-9921-5-15","journal-title":"Respir Res"},{"key":"21_CR78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fmed.2017.00093","volume":"4","author":"CN McBrien","year":"2017","unstructured":"McBrien CN, Menzies-Gow A (2017) The biology of eosinophils and their role in asthma. Front Med (Lausanne) 4:93\u201393. https:\/\/doi.org\/10.3389\/fmed.2017.00093","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"21_CR79","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1172\/jci61067","volume":"122","author":"T Jamieson","year":"2012","unstructured":"Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, Sansom OJ (2012) Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122(9):3127\u20133144. https:\/\/doi.org\/10.1172\/jci61067","journal-title":"J Clin Invest"},{"key":"21_CR80","doi-asserted-by":"publisher","unstructured":"Liu K, Wang F-S, Xu R (2020) Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol. https:\/\/doi.org\/10.1038\/s41423-020-00560-0","DOI":"10.1038\/s41423-020-00560-0"},{"issue":"7","key":"21_CR81","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00952990701407702","volume":"17","author":"SK Ramaiah","year":"2007","unstructured":"Ramaiah SK, Jaeschke H (2007) Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol Mech Methods 17(7):431\u2013440. https:\/\/doi.org\/10.1080\/00952990701407702","journal-title":"Toxicol Mech Methods"},{"issue":"7","key":"21_CR82","first-page":"395","volume":"62","author":"YS Huang","year":"1999","unstructured":"Huang YS, Wu JC, Chang FY, Lee SD (1999) Interleukin-8 and alcoholic liver disease. Zhonghua Yi Xue Za Zhi (Taipei) 62(7):395\u2013401","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"issue":"3","key":"21_CR83","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.1840180316","volume":"18","author":"DB Hill","year":"1993","unstructured":"Hill DB, Marsano LS, McClain CJ (1993) Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology (Baltimore, MD) 18(3):576\u2013580","journal-title":"Hepatology (Baltimore, MD)"},{"key":"21_CR84","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fimmu.2017.00464","volume":"8","author":"A Khanam","year":"2017","unstructured":"Khanam A, Trehanpati N, Riese P, Rastogi A, Guzman CA, Sarin SK (2017) Blockade of neutrophil\u2019s chemokine receptors CXCR1\/2 abrogate liver damage in acute-on-chronic liver failure. Front Immunol 8:464\u2013464. https:\/\/doi.org\/10.3389\/fimmu.2017.00464","journal-title":"Front Immunol"},{"issue":"10","key":"21_CR85","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/acer.13840","volume":"42","author":"F Guo","year":"2018","unstructured":"Guo F, Zheng K, Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA (2018) The Lieber-DeCarli diet-a flagship model for experimental alcoholic liver disease. Alcohol Clin Exp Res 42(10):1828\u20131840. https:\/\/doi.org\/10.1111\/acer.13840","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"21_CR86","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1053\/j.gastro.2013.02.007","volume":"144","author":"I Gukovsky","year":"2013","unstructured":"Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M (2013) Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 144(6):1199\u20131209.e1194. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.007","journal-title":"Gastroenterology"},{"issue":"31","key":"21_CR87","doi-asserted-by":"publisher","first-page":"22021","DOI":"10.1074\/jbc.M603503200","volume":"281","author":"J Wang","year":"2006","unstructured":"Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281(31):22021\u201322028. https:\/\/doi.org\/10.1074\/jbc.M603503200","journal-title":"J Biol Chem"},{"issue":"6","key":"21_CR88","doi-asserted-by":"publisher","first-page":"101042831985888","DOI":"10.1177\/1010428319858885","volume":"41","author":"H Ali","year":"2019","unstructured":"Ali H, AbdelMageed M, Olsson L, Israelsson A, Lindmark G, Hammarstr\u00f6m ML, Hammarstr\u00f6m S, Sitohy B (2019) Utility of G protein-coupled receptor 35 expression for predicting outcome in colon cancer. Tumour Biol 41(6):1010428319858885. https:\/\/doi.org\/10.1177\/1010428319858885","journal-title":"Tumour Biol"},{"issue":"2","key":"21_CR89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1349-7006.2004.tb03193.x","volume":"95","author":"S Okumura","year":"2004","unstructured":"Okumura S, Baba H, Kumada T, Nanmoku K, Nakajima H, Nakane Y, Hioki K, Ikenaka K (2004) Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci 95(2):131\u2013135. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb03193.x","journal-title":"Cancer Sci"},{"issue":"3","key":"21_CR90","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/hep.25977","volume":"58","author":"D Ellinghaus","year":"2013","unstructured":"Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weism\u00fcller TJ, Schramm C, Wittig M, Bergquist A, Bj\u00f6rnsson E, Marschall H-U, Vatn M, Teufel A, Rust C, Gieger C, Wichmann HE, Runz H, Sterneck M, Rupp C, Braun F, Weersma RK, Wijmenga C, Ponsioen CY, Mathew CG, Rutgeerts P, Vermeire S, Schrumpf E, Hov JR, Manns MP, Boberg KM, Schreiber S, Franke A, Karlsen TH (2013) Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (Baltimore, MD) 58(3):1074\u20131083","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"21_CR91","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.4049\/jimmunol.1001310","volume":"185","author":"SD Kim","year":"2010","unstructured":"Kim SD, Kim Y-K, Lee HY, Kim Y-S, Jeon SG, Baek S-H, Song D-K, Ryu SH, Bae Y-S (2010) The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection. J Immunol 185(7):4302\u20134310. https:\/\/doi.org\/10.4049\/jimmunol.1001310","journal-title":"J Immunol"},{"issue":"4","key":"21_CR92","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/infdis\/jiz498","volume":"221","author":"E Wei\u00df","year":"2019","unstructured":"Wei\u00df E, Schlatterer K, Beck C, Peschel A, Kretschmer D (2019) Formyl-peptide receptor activation enhances phagocytosis of community-acquired methicillin-resistant Staphylococcus aureus. J Infect Dis 221(4):668\u2013678. https:\/\/doi.org\/10.1093\/infdis\/jiz498","journal-title":"J Infect Dis"},{"issue":"52","key":"21_CR93","doi-asserted-by":"publisher","first-page":"18685","DOI":"10.1073\/pnas.1410938111","volume":"111","author":"T Gobbetti","year":"2014","unstructured":"Gobbetti T, Coldewey SM, Chen J, McArthur S, le Faouder P, Cenac N, Flower RJ, Thiemermann C, Perretti M (2014) Nonredundant protective properties of FPR2\/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A 111(52):18685\u201318690. https:\/\/doi.org\/10.1073\/pnas.1410938111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"21_CR94","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1900430","volume":"204","author":"M Zhang","year":"2020","unstructured":"Zhang M, Gao J-L, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM, Wang X, Wang JM (2020) A critical role of formyl peptide receptors in host defense against Escherichia coli. J Immunol 204(9):2464\u20132473. https:\/\/doi.org\/10.4049\/jimmunol.1900430","journal-title":"J Immunol"},{"issue":"8","key":"21_CR95","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.bbamcr.2013.03.026","volume":"1833","author":"H Forsman","year":"2013","unstructured":"Forsman H, Bylund J, Oprea TI, Karlsson A, Boulay F, Rabiet M-J, Dahlgren C (2013) The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop. Biochim Biophys Acta 1833(8):1914\u20131923","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"21_CR96","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1128\/aac.02716-13","volume":"58","author":"M Winther","year":"2014","unstructured":"Winther M, Gabl M, Oprea TI, J\u00f6nsson B, Boulay F, Bylund J, Dahlgren C, Forsman H (2014) Antibacterial activity of pepducins, allosterical modulators of formyl peptide receptor signaling. Antimicrob Agents Chemother 58(5):2985\u20132988. https:\/\/doi.org\/10.1128\/aac.02716-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"21_CR97","doi-asserted-by":"publisher","first-page":"33832","DOI":"10.1074\/jbc.M110.216564","volume":"286","author":"Y Guo","year":"2011","unstructured":"Guo Y, Zhang W, Giroux C, Cai Y, Ekambaram P, Dilly A-K, Hsu A, Zhou S, Maddipati KR, Liu J, Joshi S, Tucker SC, Lee M-J, Honn KV (2011) Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J Biol Chem 286(39):33832\u201333840. https:\/\/doi.org\/10.1074\/jbc.M110.216564","journal-title":"J Biol Chem"},{"issue":"6","key":"21_CR98","first-page":"1574","volume":"54","author":"YQ Chen","year":"1994","unstructured":"Chen YQ, Duniec ZM, Liu B, Hagmann W, Gao X, Shimoji K, Marnett LJ, Johnson CR, Honn KV (1994) Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 54(6):1574\u20131579","journal-title":"Cancer Res"},{"issue":"8","key":"21_CR99","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/ijc.28165","volume":"133","author":"AK Dilly","year":"2013","unstructured":"Dilly AK, Ekambaram P, Guo Y, Cai Y, Tucker SC, Fridman R, Kandouz M, Honn KV (2013) Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K\/Akt\/NF-\u03baB. Int J Cancer 133(8):1784\u20131791. https:\/\/doi.org\/10.1002\/ijc.28165","journal-title":"Int J Cancer"},{"issue":"2","key":"21_CR100","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1161\/01.HYP.37.2.334","volume":"37","author":"D Gonz\u00e1lez-N\u00fa\u00f1ez","year":"2001","unstructured":"Gonz\u00e1lez-N\u00fa\u00f1ez D, Claria J, Rivera F, Poch E (2001) Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 37(2):334\u2013338. https:\/\/doi.org\/10.1161\/01.HYP.37.2.334","journal-title":"Hypertension"},{"issue":"14","key":"21_CR101","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","volume":"124","author":"J Yeung","year":"2014","unstructured":"Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ, Luci DK, Jadhav A, Simeonov A, Maloney DJ, Holman TR, McKenzie SE, Holinstat M (2014) Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation. Blood 124(14):2271\u20132279. https:\/\/doi.org\/10.1182\/blood-2014-05-575878","journal-title":"Blood"},{"issue":"1","key":"21_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/abbi.1999.1284","volume":"368","author":"H Kamitani","year":"1999","unstructured":"Kamitani H, Ikawa H, Hsi LC, Watanabe T, DuBois RN, Eling TE (1999) Regulation of 12-lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis induced by sodium butyrate. Arch Biochem Biophys 368(1):45\u201355. https:\/\/doi.org\/10.1006\/abbi.1999.1284","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"21_CR103","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/bjc.2016.201","volume":"115","author":"CH Nguyen","year":"2016","unstructured":"Nguyen CH, Stadler S, Brenner S, Huttary N, Krieger S, J\u00e4ger W, Dolznig H, Krupitza G (2016) Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching. Br J Cancer 115(3):364\u2013370. https:\/\/doi.org\/10.1038\/bjc.2016.201","journal-title":"Br J Cancer"},{"issue":"6","key":"21_CR104","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1096\/fj.201500076","volume":"30","author":"KV Honn","year":"2016","unstructured":"Honn KV, Guo Y, Cai Y, Lee MJ, Dyson G, Zhang W, Tucker SC (2016) 12-HETER1\/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression. FASEB J 30(6):2360\u20132369. https:\/\/doi.org\/10.1096\/fj.201500076","journal-title":"FASEB J"},{"issue":"4","key":"21_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.npp.1380111","volume":"11","author":"H Hall","year":"1994","unstructured":"Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11(4):245\u2013256. https:\/\/doi.org\/10.1038\/sj.npp.1380111","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"21_CR106","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/onc.2015.369","volume":"35","author":"DC Borcherding","year":"2016","unstructured":"Borcherding DC, Tong W, Hugo ER, Barnard DF, Fox S, LaSance K, Shaughnessy E, Ben-Jonathan N (2016) Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene 35(24):3103\u20133113. https:\/\/doi.org\/10.1038\/onc.2015.369","journal-title":"Oncogene"},{"key":"21_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-211-45295-0_3","volume":"70","author":"O Hornykiewicz","year":"2006","unstructured":"Hornykiewicz O (2006) The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70:9\u201315. https:\/\/doi.org\/10.1007\/978-3-211-45295-0_3","journal-title":"J Neural Transm Suppl"},{"issue":"2","key":"21_CR108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tins.2013.11.003","volume":"37","author":"TT Winton-Brown","year":"2014","unstructured":"Winton-Brown TT, Fusar-Poli P, Ungless MA, Howes OD (2014) Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci 37(2):85\u201394. https:\/\/doi.org\/10.1016\/j.tins.2013.11.003","journal-title":"Trends Neurosci"},{"issue":"3","key":"21_CR109","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","volume":"67","author":"LS Kegeles","year":"2010","unstructured":"Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67(3):231\u2013239. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.10","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"21_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.neuropsych.24.1.1","volume":"24","author":"KH Taber","year":"2012","unstructured":"Taber KH, Black DN, Porrino LJ, Hurley RA (2012) Neuroanatomy of dopamine: reward and addiction. J Neuropsychiatry Clin Neurosci 24(1):1\u20134. https:\/\/doi.org\/10.1176\/appi.neuropsych.24.1.1","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"21_CR111","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2(8):577\u2013588. https:\/\/doi.org\/10.1038\/35086062","journal-title":"Nat Rev Neurosci"},{"issue":"13","key":"21_CR112","first-page":"59","volume":"101","author":"A Barbeau","year":"1969","unstructured":"Barbeau A (1969) L-dopa therapy in Parkinson\u2019s disease: a critical review of nine years\u2019 experience. Can Med Assoc J 101(13):59\u201368","journal-title":"Can Med Assoc J"},{"issue":"33","key":"21_CR113","doi-asserted-by":"publisher","first-page":"27806","DOI":"10.1074\/jbc.M112.388413","volume":"287","author":"E Santini","year":"2012","unstructured":"Santini E, Feyder M, Gangarossa G, Bateup HS, Greengard P, Fisone G (2012) Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism. J Biol Chem 287(33):27806\u201327812. https:\/\/doi.org\/10.1074\/jbc.M112.388413","journal-title":"J Biol Chem"},{"issue":"2","key":"21_CR114","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbrc.2005.02.040","volume":"329","author":"H Kang","year":"2005","unstructured":"Kang H, Lee WK, Choi YH, Vukoti KM, Bang WG, Yu YG (2005) Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-HT6) and the alpha subunit of GS protein. Biochem Biophys Res Commun 329(2):684\u2013692. https:\/\/doi.org\/10.1016\/j.bbrc.2005.02.040","journal-title":"Biochem Biophys Res Commun"},{"key":"21_CR115","doi-asserted-by":"publisher","unstructured":"Taylor-Whiteley TR, Le Maitre CL, Duce JA, Dalton CF, Smith DP (2019) Recapitulating Parkinson\u2019s disease pathology in a three-dimensional human neural cell culture model. Dis Model Mech 12(4). https:\/\/doi.org\/10.1242\/dmm.038042","DOI":"10.1242\/dmm.038042"},{"issue":"1","key":"21_CR116","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","volume":"12","author":"H Xicoy","year":"2017","unstructured":"Xicoy H, Wieringa B, Martens GJ (2017) The SH-SY5Y cell line in Parkinson\u2019s disease research: a systematic review. Mol Neurodegener 12(1):10. https:\/\/doi.org\/10.1186\/s13024-017-0149-0","journal-title":"Mol Neurodegener"},{"issue":"1","key":"21_CR117","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1124\/jpet.300.1.305","volume":"300","author":"DJ Pettibone","year":"2002","unstructured":"Pettibone DJ, Hess JF, Hey PJ, Jacobson MA, Leviten M, Lis EV, Mallorga PJ, Pascarella DM, Snyder MA, Williams JB, Zeng Z (2002) The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J Pharmacol Exp Ther 300(1):305\u2013313. https:\/\/doi.org\/10.1124\/jpet.300.1.305","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"21_CR118","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/j.1471-4159.2007.05205.x","volume":"105","author":"G Roussy","year":"2008","unstructured":"Roussy G, Dansereau M-A, Dor\u00e9-Savard L, Belleville K, Beaudet N, Richelson E, Sarret P (2008) Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model. J Neurochem 105(4):1100\u20131114","journal-title":"J Neurochem"},{"issue":"4","key":"21_CR119","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ejpain.2011.07.008","volume":"16","author":"A Guillemette","year":"2012","unstructured":"Guillemette A, Dansereau MA, Beaudet N, Richelson E, Sarret P (2012) Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain. Eur J Pain 16(4):473\u2013484. https:\/\/doi.org\/10.1016\/j.ejpain.2011.07.008","journal-title":"Eur J Pain"},{"issue":"42","key":"21_CR120","doi-asserted-by":"publisher","first-page":"16657","DOI":"10.1073\/pnas.0707936104","volume":"104","author":"JW Wisler","year":"2007","unstructured":"Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 104(42):16657\u201316662. https:\/\/doi.org\/10.1073\/pnas.0707936104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"21_CR121","doi-asserted-by":"publisher","first-page":"14555","DOI":"10.1073\/pnas.0804745105","volume":"105","author":"IM Kim","year":"2008","unstructured":"Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 105(38):14555\u201314560. https:\/\/doi.org\/10.1073\/pnas.0804745105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"21_CR122","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291x(89)91757-9","volume":"164","author":"A Miyata","year":"1989","unstructured":"Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164(1):567\u2013574. https:\/\/doi.org\/10.1016\/0006-291x(89)91757-9","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"21_CR123","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1124\/pr.109.001370","volume":"61","author":"D Vaudry","year":"2009","unstructured":"Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BKC, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61(3):283\u2013357. https:\/\/doi.org\/10.1124\/pr.109.001370","journal-title":"Pharmacol Rev"},{"issue":"1","key":"21_CR124","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s10194-018-0855-1","volume":"19","author":"T Hirabayashi","year":"2018","unstructured":"Hirabayashi T, Nakamachi T, Shioda S (2018) Discovery of PACAP and its receptors in the brain. J Headache Pain 19(1):28. https:\/\/doi.org\/10.1186\/s10194-018-0855-1","journal-title":"J Headache Pain"},{"key":"21_CR125","doi-asserted-by":"publisher","unstructured":"Sol\u00e9s-Tarr\u00e9s I, Cabezas-Llobet N, Vaudry D, Xifr\u00f3 X (2020) Protective effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide against cognitive decline in neurodegenerative diseases. Front Cell Neurosci 14(221). https:\/\/doi.org\/10.3389\/fncel.2020.00221","DOI":"10.3389\/fncel.2020.00221"},{"issue":"6","key":"21_CR126","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.14336\/ad.2020.0626","volume":"11","author":"Y Fang","year":"2020","unstructured":"Fang Y, Ren R, Shi H, Huang L, Lenahan C, Lu Q, Tang L, Huang Y, Tang J, Zhang J, Zhang JH (2020) Pituitary adenylate cyclase-activating polypeptide: a promising neuroprotective peptide in stroke. Aging Dis 11(6):1496\u20131512. https:\/\/doi.org\/10.14336\/ad.2020.0626","journal-title":"Aging Dis"},{"key":"21_CR127","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.neuropharm.2015.05.014","volume":"108","author":"A Lamine","year":"2016","unstructured":"Lamine A, L\u00e9tourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A (2016) Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson\u2019s disease model. Neuropharmacology 108:440\u2013450. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.014","journal-title":"Neuropharmacology"},{"issue":"6","key":"21_CR128","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/j.1460-9568.2005.03988.x","volume":"21","author":"CS Lam","year":"2005","unstructured":"Lam CS, Korzh V, Strahle U (2005) Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur J Neurosci 21(6):1758\u20131762. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.03988.x","journal-title":"Eur J Neurosci"}],"container-title":["Methods in Molecular Biology","Cell Penetrating Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1752-6_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T16:08:53Z","timestamp":1636646933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1752-6_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"ISBN":["9781071617519","9781071617526"],"references-count":128,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1752-6_21","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-0716-1752-6","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"12 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}